Contact Person

Dr. Elinor Switzer

Managing Editor

Phone: +49 (0)711 - 8931-230
Fax: +49 (0)711 - 8931-323
send an Email


Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Issue: 2013: 109/1 (Jan) pp. 1–173
Pages: 93-101

Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention

A systematic review and meta-analysis

D. Aradi (1), A. Komócsi (1), A. Vorobcsuk (1), V. L. Serebruany (2)

(1) University of Pécs, Heart Institute, Division of Interventional Cardiology, Hungary; (2) HeartDrug™ Research LLC, Johns Hopkins University, Towson, Maryland, USA


Stroke, clopidogrel, platelet inhibition, prasugrel, ticagrelor, P2Y 12 -receptor


Administration of a P2Y 12 -receptor antagonist in addition to aspirin is mandatory in patients with acute coronary syndromes (ACS) or undergoing percutaneous coronary intervention (PCI) to reduce the occurrence of thrombotic events; however, their impact on mortality and stroke is unclear. We aimed to evaluate the influence of moderate (clopidogrel) or potent (prasugrel/ticagrelor) P2Y 12 -receptor inhibition on major cardiovascular outcomes among patients with ACS or undergoing PCI. Systematic literature search was performed to find randomised, controlled clinical trials comparing the clinical impact of clopidogrel with placebo or prasugrel/ticagrelor versus clopidogrel. Outcome measures included cardiovascular death, myocardial infarction (MI), total stroke and intracranial haemorrhage (ICH). Random-effects model with Mantel-Heanszel weighting was used to pool outcomes into a meta-analysis. Four studies comparing clopidogrel with placebo and five trials comparing clopidogrel with new P2Y 12 -receptor inhibitors were identified including a total of 107,473 patients. Compared to placebo, clopidogrel reduced the risk of cardiovascular death (odds ratio [OR]: 0.93; 95% confidence interval [CI]: 0.87–0.99, p=0.02), MI (OR 0.80; 95%CI 0.74–0.88, p<0.00001) and stroke (OR 0.84; 95%CI 0.72–0.97, p=0.02), without influencing risk for ICH (OR 0.96; 95%CI 0.69–1.33, p=0.79). Treatment with prasugrel/ticagrelor provided additional benefit over clopidogrel regarding cardiovascular mortality (OR 0.86; 95%CI 0.78–0.94, p=0.002) and MI (OR: 0.83; 95%CI 0.74–0.93, p<0.001), but no advantage in stroke (OR: 1.06; 95%CI 0.88–1.26, p=0.55) and in ICH (OR: 1.16; 95%CI 0.75–1.81; p=0.49) was observed. Increased potency of P2Y 12 -receptor inhibition is associated with decreased risk in cardiovascular death and MI; however, this association is not true in case of stroke, where potent P2Y 12 -receptor antagonists have no incremental benefit over clopidogrel.

You may also be interested in...


Online Supplementary Material

D. Kiers (1, 2), W. A. van der Heijden (3), L. van Ede (1), J. Gerretsen (1), Q. de Mast (3), A. J. van der Ven (3), S. el Messaoudi (4), G. A. Rongen (3, 4), M. Gomes (5), M. Kox (1), P. Pickkers (1), N. P. Riksen (3)

Thromb Haemost 2017 117 9: 1798-1807


Online Supplementary Material

F. Rollini (1), F. Franchi (1), K. Singh (1), J. R. Cho (1), M. Bhatti (1), C. DeGroat (1), J. Hu (1), N. Aggarwal (1), Z. Alobaidi (1), E. Thano (1), E. Ferrante (1), M. Zenni (1), T. A. Bass (1), D. J. Angiolillo (1)

Thromb Haemost 2016 116 6: 1060-1069


See also De Caterina

V. L. Serebruany (1), V. Cherepanov (1), H. A. Cabrera-Fuentes (2, 3, 4, 5), M. H. Kim (6)

Thromb Haemost 2015 114 6: 1104-1112